In addition, Alnylam secured an option to advance Takeda’s RNAi therapeutic programs in the U.S. on a 50-50 basis.

Takeda Pharmaceutical obtained worldwide, nonexclusive access to Alnylam Pharmaceuticals’ RNAi therapeutics platform and IP in the fields of oncology and metabolic disease. The partnership includes $100 million upfront and $50 million in near-term technology-transfer payments for a nonexclusive license in two therapeutic fields.


The deal is valued at potentially over $1 billion in future R&D and commercial milestones, upon successful commercialization of multiple products. Alnylam is also eligible to receive R&D funding related to the drug discovery collaboration.


At Takeda’s option, the scope of the partnership can be expanded to include additional fields with a $50 million per field expansion payment. In addition, Alnylam is eligible to receive up to $171 million in development and commercial milestone payments and significant royalties per product.


Also benefitting from the deal is Isis Pharmaceuticals, which will receive $4.6 million from Alnylam Pharmaceuticals as its portion of the upfront fees. Isis has the potential to receive a piece of future milestone and royalty payments as well.


In 2004, Alnylam obtained an exclusive license to Isis’ intellectual property for double-stranded oligonucleotide therapeutics that mediate RNAi. In return, Isis received an upfront payment and financial participation in future transactions supported by Isis’ patents.


The agreement between Alnylam and Takeda includes the transfer of platform technology from Alnylam to Takeda, a collaboration and cross-license of delivery technologies between the two companies, and a drug discovery partnership on certain RNAi therapeutic targets, subject to certain Alnylam third-party obligations.


As part of the deal, Takeda becomes Alnylam’s strategic partner for RNAi therapeutics over a five-year period and the only Asian company to obtain a right of first negotiation to develop and commercialize Alnylam RNAi therapeutic programs for the Asian market. The deal, however, excludes Alnylam’s ALN-RSV01 program. In addition, Alnylam obtains opt-in options to codevelop and co-ommercialize Takeda RNAi therapeutics in the U.S. market on a 50-50 basis.

Previous articleEmergent BioSolutions Picks Up Protein Sciences for $48M
Next articleBAC to Develop Custom Ligand to Purify LFB and GTC’s Recombinant Factor VIIa